Evaluating cognitive outcome measures for MS clinical trials: What is a clinically meaningful change?

Multiple Sclerosis Journal

Volumn 18, Issue 12, 2012, Pages 1673-1679

  Benedict, Ralph Hb ^a   Walton, Marc K ^b  

^a UNIVERSITY AT BUFFALO   (United States)

^b CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

clinically meaningful change; cognitive impairment; cognitive tests; memory; Multiple sclerosis; neuropsychology; outcome measurement; processing speed; study design; vocational disability

Indexed keywords

COGNITIVE DEFECT; HUMAN; MOTOR PERFORMANCE; MULTIPLE SCLEROSIS; NEUROPSYCHOLOGICAL TEST; PSYCHOMETRY; QUANTITATIVE ANALYSIS; REVIEW; SELF REPORT; TEST RETEST RELIABILITY; TREATMENT OUTCOME; VALIDITY;

EID: 84871541823     PISSN: 13524585     EISSN: 14770970     Source Type: Journal    
DOI: 10.1177/1352458512454774     Document Type: Review

References (46)

1. Langdon DW. Cognition in multiple sclerosis. Curr Opin Neurol. 2011 ; 24: 244-249
2. Chiaravalloti ND, DeLuca J. Cognitive impairment in multiple sclerosis. Lancet Neurol. 2008 ; 7: 1139-1151
3. Benedict RHB, Zivadinov R. Risk factors for and management of cognitive dysfunction in multiple sclerosis. Nat Rev Neurol. 2011 ; 7: 332-342
4. Guidance for Industry Patient-Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims. In. Rockville, MD, USA: US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER), Center for Devices and Radiological Health (CDRH). US Food and Drug Adminstration. Guideance for Industry: Patient Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims. 2009. Available from: http://www.dfd.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/UCM193282.pdf [Accessed June 2012].
5. Langdon D, Amato M, Boringa J, et al. Recommendations for a brief international cognitive assessment for multiple sclerosis (BICAMS). Mult Scler. 2011 ;:
6. Peyser JM, Rao SM, LaRocca NG, et al. Guidelines for neuropsychological research in multiple sclerosis. Arch Neurol. 1990 ; 47: 94-97
7. Benedict RHB, Fischer JS, Archibald CJ, et al. Minimal neuropsychological assessment of MS Patients: A consensus approach. Clin Neuropsychol. 2002 ; 16: 381-397
8. BenedictRHBKruppLFrancisG. NINDS common data elements, multiple sclerosis, neuropsychology/cognition recommendations. NINDS (National Institute of Neurological Disorders and Stroke). http://www.commondataelements.ninds.nih. gov/CRFs/Neuropsychology,%20Cognition%20Recommendations%20- %20Adult%20and%20Pediatric.doc?CrfId=1180.[accessed July 2012].
9. Jaeschke R, Singer J, Guyatt GH. Measurement of health status. Ascertaining the minimal clinically important difference. Control Clin Trials. 1989 ; 10: 407-415
10. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS). Ann Neurol. 1983 ; 13: 227-231
11. Temkin NR, Heaton R, Grant I, Dikmen SS. Detecting significant change in neuropsychological test performance: a comparison of four models. J Int neropsychol Soc. 1999 ; 5: 357-369
12. Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet. 1986 ; 1: 307-310
13. Chatburn RL. Evaluation of instrument error and method agreement. J Am Ass Nurse Anesthesiol. 1996 ; 64: 261-262
14. Atkinson G, Nevill AM. Statistical methods for assessing measurement error (reliability) in variables relevant to sports medicine. Sports Med. 1998 ; 26: 217-238
15. Schwid SR, Goodman AD, Mattson DH, et al. The measurement of ambulatory impairment in multiple sclerosis. Neurol. 1997 ; 49: 1419-1424
16. Smith A Symbol digit modalities test: Manual. Los Angeles: Western Psychological Services ; 1982 :
17. Mathiowetz V, Weber K, Kashman N, et al. Adult norms for the nine hole peg test of finger dexterity. Occup Ther J Res. 1985a ; 5: 25-38
18. Hoogervorst EL, Kalkers NF, Cutter GR, et al. The patient's perception of a (reliable) change in the Multiple Sclerosis Functional Composite. Mult Scler. 2004 ; 10: 55-60
19. Kragt JJ, Van der Linden FA, Nielsen JM, et al. Clinical impact of 20% worsening on timed 25-foot walk and 9-hole peg test in multiple sclerosis. Mult Scler. 2006 ; 12: 594-598
20. Sharrack B, Hughes RA. The Guy's Neurological Disability Scale (GNDS): A new disability measure for multiple sclerosis. Mult Scler. 1999 ; 5: 223-233
21. Van Winsen LM, Kragt JJ, Hoogervorst EL, et al. Outcome measurement in multiple sclerosis: Detection of clinically relevant improvement. Mult Scler. 2010 ; 16: 604-610
22. Kaufman M, Moyer D, Norton J. The significant change for the timed 25-foot walk in the multiple sclerosis functional composite. Mult Scler. 2000 ; 6: 286-290
23. Schwid SR, Goodman AD, McDermott MP, et al. Quantitative functional measures in MS: What is a reliable change?. Neurol. 2002 ; 58: 1294-1296
24. Benedict RHB, Cox D, Thompson LL, et al. Reliable screening for neuropsychological impairment in MS. Mult Scler. 2004 ; 10: 675-678
25. Benedict RHB, Munschauer F, Linn R, et al. Screening for multiple sclerosis cognitive impairment using a self-administered 15-item questionnaire. Mult Scler. 2003 ; 9: 95-101
26. Carone D, Benedict RHB, Munschauer FE, et al. Interpreting patient/informant discrepancies of reported cognitive symptoms in MS. J Int Neuropsychol Soc. 2005 ; 11: 574-583
27. O'Brien A, Gaudino-Goering E, Shawaryn M, et al. Relationship of the Multiple Sclerosis Neuropsychological Questionnaire (MSNQ) to functional, emotional, and neuropsychological outcomes. Arch Clin Neuropsychol. 2007 ; 22: 933-948
28. Christodoulou C, Melville P, Scherl WF, et al. Perceived cognitive dysfunction and observed neuropsychological performance: Longitudinal relation in persons with multiple sclerosis. J Int Neuropsychol Soc. 2005 ; 11: 614-619
29. Benedict RHB, Zivadinov R. Predicting neuropsychological abnormalities in multiple sclerosis. J Neurol Sci. 2006 ; 245: 67-72
30. Vanotti S, Benedict RHB, Acion L, et al. Validation of the multiple sclerosis neuropsychological screening questionnaire in Argentina. Mult Scler. 2009 ; 15: 244-250
31. Julian L, Merluzzi NM, Mohr DC. The relationship among depression, subjective cognitive impairment, and neuropsychological performance in multiple sclerosis. Mult Scler. 2007 ; 13: 81-86
32. Krupp LB, Christodoulou C, Melville P, et al. Donepezil improves memory in multiple sclerosis in a randomized clinical trial. Neurol. 2004 ; 63: 1579-1585
33. Krupp LB, Christodoulou C, Melville P, et al. Multicenter randomized clinical trial of donepezil for memory impairment in multiple sclerosis. Neurol. 2011 ; 76: 1500-1507
34. Morrow SA, Kaushik T, Zarevics P, et al. The effects of L-amphetamine sulfate on cognition in MS patients: Results of a randomized controlled trial. J Neurol. 2009 ; 256: 1095-1102
35. Owsley C, Sloane M, McGwin G, et al. Timed instrumental activities of daily living tasks: Relationship to cognitive function and everyday performance assessments in older adults. Gerontol. 2002 ; 48: 254-265
36. Baum C, Morrison T, Hahn M, et al Test manual for the Executive Function Performance Test. St. Louis, MO: Washington University ; 2003 :
37. Goverover Y, Genova HM, Hillary FG, et al. The relationship between neuropsychological measures and the timed instrumental activities of daily living task in multiple sclerosis. Mult Scler. 2007 ; 13: 636-644
38. Kalmar JH, Gaudino EA, Moore NB, et al. The relationship between cognitive deficits and everyday functional activities in multiple sclerosis. Neuropsychol. 2008 ; 22: 442-449
39. Voelbel GT, Goverover Y, Gaudino EA, et al. The relationship between neurocognitive behavior of executive functions and the EFPT in individuals with multiple sclerosis. OTJR. 2011 ; 31: S30-37
40. Goverover Y, O'Brien AR, Moore NB, et al. Actual reality: A new approach to functional assessment in persons with multiple sclerosis. Arch Phys Med Rehabil. 2010 ; 91: 252-260
41. Morrow SA, Drake AS, Zivadinov R, et al. Predicting loss of employment over three years in multiple sclerosis: Clinically meaningful cognitive decline. Clin Neuropsychol. Year ; 24: 1131-1145
42. Delis DC, Kramer JH, Kaplan E, et al California verbal learning test. 2 nd ed.San Antonio, TX: The Psychological Corporation, 2000. San Antonio, TX: The Psychological Corporation ; 2000 :
43. Benedict RHB. Effects of using same vs. alternate form memory tests in short-interval, repeated assessment in multiple sclerosis. J Int Neuropsychol Soc. 2005 ; 11: 727-736
44. Benedict RHB, Wahlig E, Bakshi R, et al. Predicting quality of life in multiple sclerosis: Accounting for physical disability, fatigue, cognition, mood disorder, personality, and behavior change. J Neurol Sci. 2005 ; 231: 29-34
45. Benedict RHB, Cookfair D, Gavett R, et al. Validity of the minimal assessment of cognitive function in multiple sclerosis (MACFIMS). J Int Neuropsychol Soc. 2006 ; 12: 549-558
46. Sumowski JF, Chiaravalloti N, Erlanger D, et al. L-amphetamine improves memory in MS patients with objective memory impairment. Mult Scler. 2011 ; 17: 1141-1145